Everfront Biotech will participate in BIO 2024

Date: April 15, 2024

Everfront Biotech will participate in the BIO 2024 International Convention held in San Diego, USA, from June 3rd to June 6th, 2024. This event is the annual flagship event in the global biotech industry. We welcome your visit and participation.

Everfront Biotech will attend the BIO 2024 International Convention, held in San Diego, United States, from June 3rd to June 6th, 2024. This event is recognized as the largest international exhibition and forum in the global biotechnology industry, representing the pinnacle of the biotech world annually. We will join the Taiwan Biotech Delegation and exhibit at Booth 1817 & 1917 within the Taiwan Pavilion, alongside 54 other elite domestic companies. We will showcase Everfront Biotech’s recent clinical achievements, aiming to align Taiwan’s biotech capabilities with the international community and seize more international collaboration opportunities. You can reach out to us throughout the event to discuss the unique challenges you encounter in new drug development, potential partnership opportunities, and embark on the journey to success in new drug development together. We look forward to your visit and participation.

Key Highlights of Our Exhibition:

Pioneering a Better Future for Brain Cancer Treatment

We are shaping the future with Cerebraca® Wafer, an orphan drug designated by the USFDA for the treatment of high-grade glioma (GBM). This locally-sustained delivery treatment offers hope for patients with GBM, who currently face a median survival of only 6-9 months with current therapies. Our Phase I trial results are promising, demonstrating a remarkable 26.2-month median overall survival – a significant improvement. We are now initiating a global Phase IIb pivotal study to seek regulatory approval.

Breaking Through Barriers

Cerebraca® Wafer, manufactured under PIC/S GMP standards, utilizes EF-API-001 to target the Axl1-mTOR-PD-L1/MGMT axis. Delivered directly through a biodegradable wafer implanted after surgery, Cerebraca® Wafer overcomes a major challenge in brain tumor treatment – the blood-brain barrier and the tumor microenvironment with resistance and immune suppression. This localized, sustained delivery inhibits residual tumor stem cells, reduces chemoresistance, and enhances immune response. Also, it brings a better quality of life to patients.

Join us in shaping the future of cancer treatment.

Bio one-on-one partnering:

Learn more >> about Cerebraca® Wafer and our pipeline.

BIO 2024: https://convention.bio.org/

Exhibition Information:

Everfront Biotech Inc. cordially invites you to participate in the 2024 Taiwan Smart Health Gala

  • Topic: Taiwan Start Up Pitch
  • Date: June 3rd (Monday) 
  • Time: 10:15 – 11:35
  • Venue: Marriott Marquis San Diego Marina, Grand Ballroom B

Everfront Biotech Inc. cordially invites you to participate in the BIO2024 Start-up Stadium.


Date: June 4, 2024
Time: 2:30 – 2:40 PM
URL:  https://convention.bio.org/program/start-up-stadium
Product Highlights of Cerebraca® Wafer:

Everfront Biotech’s innovative new drug, Cerebraca® Wafer, is a precision medicine sustained-release wafer that revolutionizes the treatment of malignant brain cancer. Through multiple patented novel features, Cerebraca® Wafer has successfully addressed the challenges of treating malignant brain cancer, which is difficult to manage and prone to relapse. Chemotherapy gradually loses its effectiveness against brain cancer cells due to their drug resistance, and the high proportion of cancer stem cells further exacerbates the problem of cancer recurrence and treatment resistance. However, these issues can be addressed by the pharmacological mechanism of action of Cerebraca® Wafer. In addition, malignant brain cancer cells express PD-L1, which renders the immune system unable to kill cancer cells. The successful development of Cerebraca® Wafer has also addressed this issue. In Phase I clinical trials, Cerebraca® Wafer has demonstrated efficacy without any drug-related adverse reactions. The median or average cumulative survival of relapsed malignant brain cancer patients has reached 25-26 months, which is significantly better than existing strategies such as Gliadel® wafer implantation (6.4 months), Temodal capsules (5.8 months), or Avastin injection (9.4 months). Cerebraca® Wafer has been approved by the Taiwan Ministry of Health and Welfare and the Human Research Ethics Committee of Hualien Tzu Chi Hospital for compassionate use trials. For malignant brain cancer patients who cannot undergo surgery and have tumors growing at the cervical spine, implanting Cerebraca® Wafer through a small incision has resulted in tumor shrinkage. In addition, combining Cerebraca® Wafer with cytokine-induced killer cells (CIK) for treatment can achieve a recurrence-free survival period of more than 40 months. With its outstanding clinical results, Everfront Biotech Inc. is actively seeking partners to jointly develop this new drug and help more malignant brain cancer patients.

Introduction to Everfront Biotech Inc.:

Everfront Biotech Inc. targets unmet medical needs by developing orphan drugs to treat some of the world’s most lethal diseases. Founded in 2010, the company focuses on the research and development of new drugs, emphasizing the screening of potential small molecules and advancing them to clinical trials. From initial product development to preclinical research, chemical manufacturing and control, new drug clinical trial applications, clinical trial planning, and execution, all these tasks are led by the company’s dedicated team.

Currently, Everfront has three clinical trials approved in the United States and Taiwan, including Cerebraca® Wafer (for malignant brain tumors)HK-001 (for amyotrophic lateral sclerosis), and EF-009 (for pancreatic cancer).

Everfront Biotech actively aligns with national new drug development policies. Both Cerebraca® Wafer and HK-001 have received biotech new drug certification. The company also actively participates in national projects, with three special projects and one SBIR project receiving funding from the Ministry of Economic Affairs. 

Development Pipeline